Information Provided By:
Fly News Breaks for July 23, 2018
Jul 23, 2018 | 06:05 EDT
Piper Jaffray analyst David Amsellem reiterates an Underweight rating on Bausch Health Companies, formerly named Valeant Pharmaceuticals, with a $13 price target. The analyst continues to have "myriad concerns" regarding the commercial portfolio and pipeline, namely doubts regarding where and when EBITDA will trough. He does not believe the current valuation is "logical" given Bausch's "significant exposure to mature assets with questionable durability and leverage ratios that are still very much an eyesore."